Experimental Hematology
Volume 38, Issue 1 , Pages 61-70 , January 2010

Preclinical development of a bridging therapy for radiation casualties

  • Vijay K. Singh

      Affiliations

    • Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute, F. Edward Hebért School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • Department of Radiation Biology, F. Edward Hebért School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • Corresponding Author InformationOffprint requests to: Vijay K. Singh, Ph.D., Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, 8901 Wisconsin Avenue, Bethesda, MD 20889-5603
    • ,
  • Darren S. Brown

      Affiliations

    • Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute, F. Edward Hebért School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • ,
  • Tzu-Cheg Kao

      Affiliations

    • Division of Epidemiology and Biostatistics, Department of Preventive Medicine and Biometrics, F. Edward Hebért School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • ,
  • Thomas M. Seed

      Affiliations

    • Tech Micro Services, Bethesda, Md., USA

Received 8 September 2009 ,Revised 11 October 2009 ,Accepted 15 October 2009.

References 

  1. Benjamin GC, McGeary M, McCutchen SR. Assessing medical preparedness to respond to a terrorist nuclear event: workshop report. Washington, DC: The National Academies Press; 2009;
  2. Singh VK, Seed TM. Radiation Effects. In:  Roy MJ editors. Physician's guide to terrorist attack. Totowa: Humana Press; 2003;p. 339–362
  3. Koenig KL, Goans RE, Hatchett RJ, et al. Medical treatment of radiological casualties: current concepts. Ann Emerg Med. 2005;45:643–652
  4. Meineke V, van Beuningen D, Sohns T, Fliedner TM. Medical management principles for radiation accidents. Mil Med. 2003;168:219–222
  5. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM. The hematologist and radiation casualties. Hematology Am Soc Hematol Educ Program. 2003;473–496
  6. Seed TM. Radiation protectants: current status and future prospects. Health Phys. 2005;89:531–545
  7. Pellmar TC, Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res. 2005;163:115–123
  8. Augustine AD, Gondre-Lewis T, McBride W, Miller L, Pellmar TC, Rockwell S. Animal models for radiation injury, protection and therapy. Radiat Res. 2005;164:100–109
  9. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov Today. 2007;12:794–805
  10. Ghosh SP, Kulkarni S, Hieber K, et al. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol. 2009;85:598–606
  11. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol. 2003;23:379–385
  12. Whitnall MH, Elliott TB, Harding RA, et al. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. Int J Immunopharmacol. 2000;22:1–14
  13. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320:226–230
  14. Srinivasan V, Doctrow S, Singh VK, Whitnall MH. Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30:271–290
  15. DiCarlo AL, Hatchett RJ, Kaminski JM, et al. Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. report of an NIAID Workshop, March 26–27, 2007. Radiat Res. 2008;169:712–721
  16. Weiss JF, Landauer MR. History and development of radiation-protective agents. Int J Radiat Biol. 2009;85:539–573
  17. Xiao M, Whitnall MH. Pharmacological countermeasures for the acute radiation syndrome. Curr Mol Pharmacol. 2009;2:122–133
  18. Herodin F, Grenier N, Drouet M. Revisiting therapeutic strategies in radiation casualties. Exp Hematol. 2007;35:28–33
  19. Herodin F, Drouet M. Myeloprotection following cytotoxic damage: the sooner the better. Exp Hematol. 2008;36:769–770Author reply 771–762
  20. Herodin F, Mayol JF, Mourcin F, Drouet M. Which place for stem cell therapy in the treatment of acute radiation syndrome?. Folia Histochem Cytobiol. 2005;43:223–227
  21. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer. 2008;123:739–752
  22. Zhao Y, Neuzil J, Wu K. Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside?. Mol Nutr Food Res. 2009;53:129–139
  23. Singh VK, Brown DS. T.C.K. Tocopherol succinate: a promising radiation countermeasure. Int Immunopharmacol. 2009;9:1423–1430
  24. Singh VK, Shafran RL, Jackson WE, Seed TM, Kumar KS. Induction of cytokines by radioprotective tocopherol analogs. Exp Mol Pathol. 2006;81:55–61
  25. Ross J, Li L. HSC mobilization: new incites and insights. Blood. 2009;114:1283–1284
  26. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867–1874
  27. Pulliam AC, Hobson MJ, Ciccone SL, et al. AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp Hematol. 2008;36:1084–1090
  28. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–1318
  29. Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114:1340–1343
  30. Grande T, Bueren JA. The mobilization of hematopoietic progenitors to peripheral blood is predictive of the hematopoietic syndrome after total or partial body irradiation of mice. Int J Radiat Oncol Biol Phys. 2006;64:612–618
  31. Mehrotra S, Mishra KP, Maurya R, Srimal RC, Singh VK. Immunomodulation by ethanolic extract of Boerhaavia diffusa roots. Int Immunopharmacol. 2002;2:987–996
  32. Herodin F, Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp Hematol. 2005;33:1071–1080
  33. Herodin F, Bourin P, Mayol JF, Lataillade JJ, Drouet M. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival. Blood. 2003;101:2609–2616
  34. Drouet M, Mathieu J, Grenier N, Multon E, Sotto JJ, Herodin F. The reduction of in vitro radiation-induced Fas-related apoptosis in CD34+ progenitor cells by SCF, FLT-3 ligand, TPO, and IL-3 in combination resulted in CD34+ cell proliferation and differentiation. Stem Cells. 1999;17:273–285
  35. Drouet M, Mourcin F, Grenier N, et al. [The effects of ionizing radiation on stem cells and hematopoietic progenitors: the place of apoptosis and the therapeutic potential of anti-apoptosis treatments] Can J Physiol Pharmacol. 2002;80:700–709
  36. Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant. 2001;27(Suppl 2):S23–S29
  37. Khoury H, Adkins D, Brown R, et al. Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25:1197–1201
  38. Paydas S, Sahin B, Seyrek E, et al. Sweet's syndrome associated with G-CSF. Br J Haematol. 1993;85:191–192
  39. Singh VK, Shafran RL, Inal CE, Jackson WE, Whitnall MH. Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacol Immunotoxicol. 2005;27:521–534
  40. Singh VK, Jacobsen KO, Grace MB, et al. Administration of 5-androstenediol to mice: Pharmacokinetics and gene expression. Exp Mol Pathol. 2008;84:178–188
  41. Singh VK, Grace MB, Parekh VI, Whitnall MH, Landauer MH. Effects of genistein administration on cytokine induction in whole-body gamma irradiated mice. Int Immunopharmacol. 2009;9:1401–1410
  42. Cameron JR, Skofronick JG, Grant RM. Physics of the body. 2nd ed. Madison, WI: Medical Physics Publishing; 1999;
  43. Riches AC, Sharp JG, Thomas DB, Smith SV. Blood volume determination in the mouse. J Physiol. 1973;228:279–284
  44. Reuter S, Lang D. Life span of monocytes and platelets: importance of interactions. Front Biosci. 2009;14:2432–2447
  45. Saeki Y, Tada K, Sano T, Takahashi Y. Platelet kinetics after transfusion. Biopharm Drug Dispos. 1996;17:71–79

PII: S0301-472X(09)00399-3

doi: 10.1016/j.exphem.2009.10.008

Experimental Hematology
Volume 38, Issue 1 , Pages 61-70 , January 2010

Article Tools

* Image Usage & Resolution